Research [2013] Jul 24
[Epub ahead of print] (M.Takanashi, Y.Shimo, T.Hatano, G.Oyama, N.Hattori)
Changing from Immediate release Pramipexole to Extended release Pramipexole was found to cause a reduction in Parkinson's Disease symptoms. Pramipexole, which is marketed as Mirapex, Mirapexin, and Sifrol, is a dopamine agonist used in the treatment of Parkinson's Disease. For more information go to Mirapex and Mirapex ER.
Changing from Immediate release Pramipexole to Extended release Pramipexole was found to cause a reduction in Parkinson's Disease symptoms. Pramipexole, which is marketed as Mirapex, Mirapexin, and Sifrol, is a dopamine agonist used in the treatment of Parkinson's Disease. For more information go to Mirapex and Mirapex ER.
This study aimed to evaluate the efficacy and safety of an extended-release tablet formulation of pramipexole (PPX-ER) given once daily when switched from an immediate-release tablet formulation (PPX-IR) given 3 times daily. The extended release version evens out the effect of Pramipexole. Parkinson's Disease symptom scores were reduced after 4 weeks and after 8 weeks. There was no change in the nocturnal and early morning symptoms (NEMS) score, or the Parkinson's Disease Sleep Scale (PDSS-2). Nearly two thirds of patients and caregivers preferred the extended release version.
No comments:
Post a Comment